According to the IMARC Group, travel vaccines market report by IMARC Group, the market was worth US$ 2.94 Billion in 2020. Looking forward, the market is expected to continue its moderate growth during the next five years.
Travel vaccines are immunization shots that travelers can get before traveling to other parts of the world where there is a high risk of developing certain diseases. These vaccines build immunity against viral and microbial invasions while improving the overall health of the individual. They introduce the disease-causing microbes into the bloodstream to help the human body develop antibodies to fight off the same, if exposed to in the future. These shots must be taken at least 4 to 6 weeks before traveling as this gives enough time for the immunization to start working efficiently.
Report Metric
Historical: 2015-2020
Base Year: 2020
Forecast Year: 2021-2026
Request For Free Sample Pdf Copy @ https://www.imarcgroup.com/travel-vaccines-market/requestsample
Some of the major players operating in the industry include
- Novartis AG ADR (NVS)
- GlaxoSmithKline plc (GSK)
- Sanofi S.A. (SAN)
- Merck & Co. Inc. (MRK)
- Pfizer (NYSE: PFE)
- ALK-Abelló
- Bavarian Nordic
- Crucell N.V.
- CSL Limited
- MedImmune, LLC,
- Altimmune
- Abbott Laboratories
- F. Hoffman-La Roche Ltd.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/travel-vaccines-market
Global Travel Vaccines Market Trends:
Rising occurrence of infectious and travel-related diseases such as Japanese encephalitis, diphtheria, meningitis and yellow fever is one of the major factors that are driving the growth of the market. In addition to this, owing to factors such as the rising globalization and reduced international airfares, there has been an increase in international tourism. Consequently, the sales of travel vaccines have also witnessed a significant rise across the globe. Apart from this, several combination vaccines are also available for travelers, which protect against more than one disease. They are widely gaining popularity amongst the users as they reduce the number of vaccines required.
Furthermore, government bodies in several countries are investing in promoting the use of these vaccines. For instance, the National Health Service (NHS) is providing several free travel vaccines for diseases such as cholera, polio, typhoid and hepatitis A in the United Kingdom to reduce the risk of these diseases being spread across the country.
Note: As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Market Segmentation:
Market Breakup by Composition
- Mono Vaccines
- Combination Vaccines
Market Breakup by Disease
- Hepatitis A
- DPT
- Yellow Fever
- Typhoid
- Hepatitis B
- Measles and Mumps
- Rabies
- Meningococcal
- Varicella
- Japanese Encepthalitis
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Do You Have Any Query or Specific Requirement? Ask to Our Industry Expert: https://www.imarcgroup.com/request?type=report&id=1155&flag=C
Browse related reports
H1N1 Vaccines Market Research Report and Forecast
Indian Vaccine Market Research Report and Forecast
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
